Literature DB >> 8182939

Increased GD3 ganglioside in plasma of children with T-cell acute lymphoblastic leukemia.

W D Merritt1, V Der-Minassian, G H Reaman.   

Abstract

The presence of tumor-associated GD3 in the plasma of 12 patients with T-cell acute lymphoblastic leukemia (T-ALL) was determined utilizing microscale ganglioside isolation and thin layer chromatography (TLC) immunodetection with an anti-GD3 monoclonal antibody, R24. Immunostaining of control plasma gangliosides revealed two nearly equal subspecies groups of GD3, GD3U and GD3L. Plasma from those T-ALL patients with a high R24-positive lymphoblast count (> 60,000/mm3) had a significant increase in total GD3 and each of the GD3 subspecies groups, and a disproportionate increase in GD3L resulted in an increased ratio GD3L/GD3U in these samples. In contrast, total GD3, GD3 subspecies, and GD3L/GD3U was not increased in plasma from those cases with low R24-positive blast count (< 20,000/mm3) or in pre-B ALL plasma. The altered GD3 content in R24-positive T-ALL plasma was reversible, since total GD3 and GD3L/GD3U in plasma from a patient in remission from R24-positive T-ALL was near that of controls. Resorcinol staining of TLC-separated gangliosides confirmed the results observed with R24 detection methods. The results strongly suggest that GD3 is shed in vivo from T-ALL blasts in patients with R24-positive T-ALL, resulting in both qualitative and quantitative changes in circulating GD3 in these patients.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8182939

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  5 in total

1.  Interaction of fibroblast growth factor-2 (FGF-2) with free gangliosides: biochemical characterization and biological consequences in endothelial cell cultures.

Authors:  M Rusnati; E Tanghetti; C Urbinati; G Tulipano; S Marchesini; M Ziche; M Presta
Journal:  Mol Biol Cell       Date:  1999-02       Impact factor: 4.138

2.  Tumor gangliosides accelerate murine tumor angiogenesis.

Authors:  Yihui Liu; Assefa Wondimu; Su Yan; Daniel Bobb; Stephan Ladisch
Journal:  Angiogenesis       Date:  2013-10-29       Impact factor: 9.596

Review 3.  Neuroblastoma Origin and Therapeutic Targets for Immunotherapy.

Authors:  Irina V Kholodenko; Daniel V Kalinovsky; Igor I Doronin; Sergey M Deyev; Roman V Kholodenko
Journal:  J Immunol Res       Date:  2018-07-11       Impact factor: 4.818

Review 4.  Don't sugarcoat it: How glycocalyx composition influences cancer progression.

Authors:  Alexander Buffone; Valerie M Weaver
Journal:  J Cell Biol       Date:  2020-01-06       Impact factor: 10.539

Review 5.  Ganglioside GD3 synthase (GD3S), a novel cancer drug target.

Authors:  Jinyi Liu; Xiangjin Zheng; Xiaocong Pang; Li Li; Jinhua Wang; Cui Yang; Guanhua Du
Journal:  Acta Pharm Sin B       Date:  2018-07-25       Impact factor: 11.413

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.